Kepler Capital Markets set a €106.00 ($123.26) price target on Merck KGaA (FRA:MRK) in a research note published on Wednesday morning. The brokerage currently has a buy rating on the healthcare company’s stock.

MRK has been the subject of several other research reports. UBS Group set a €115.00 ($133.72) price objective on shares of Merck KGaA and gave the stock a buy rating in a research report on Tuesday, June 26th. Nord/LB set a €82.00 ($95.35) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research report on Thursday, August 9th. Warburg Research set a €100.00 ($116.28) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research report on Wednesday, September 12th. Goldman Sachs Group set a €92.00 ($106.98) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research report on Wednesday, September 12th. Finally, Deutsche Bank set a €91.00 ($105.81) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research report on Monday, July 30th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of €98.81 ($114.89).

Shares of MRK stock opened at €86.26 ($100.30) on Wednesday. Merck KGaA has a 52 week low of €76.60 ($89.07) and a 52 week high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Further Reading: What is the balance sheet?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.